Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Long‐term, prolonged‐release tacrolimus‐based immunosuppression in de novo kidney transplant recipients: 5‐year prospective follow‐up of the ADHERE study patients

Transplant International(2020)10.1111/tri.13527Source: DataRank Database

Long‐term, prolonged‐release tacrolimus‐based immunosuppression in de novo kidney transplant recipients: 5‐year prospective follow‐up of the ADHERE study patients is a research paper published in Transplant International (2020). On theSindex it has a DataRank of 0.388. It has been cited 7 times, with 4 citing works in its 1-hop citation network.

N/A

0.388DataRank · unranked

Scored on demand from live citation data

7 citations · 4 citing works in its network

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 0.49)OA: hybridTopics (34)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 80%Citation Network 20%

Base Score Contribution

0.312

From this paper's citation signal

Citation Network Contribution

0.0765

From 3 citing papers with measurable signal

Learn more about DataRank methodology →

Authors (15)

Mario Carmellini,Nassim Kamar ORCID,Antoine Durrbach ORCID,Christiane Mousson,Flavia Caputo

Live enrichment

PubMed:31536654 OpenAlex:https://openalex.org/W2973453908

Astellas Pharma Europe

Astellas Pharma Europe, Ltd

FWCI

0.49

Citation Percentile

0.6%

Citation Trend

2021

2022

2023

2024

hybridLicense: cc-by-nc

journalhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/tri.13527

publisherhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/tri.13527

publisherhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Ftri.13527

publisherhttps://onlinelibrary.wiley.com/doi/pdf/10.1111/tri.13527

publisherhttps://onlinelibrary.wiley.com/doi/full-xml/10.1111/tri.13527

Fields of Study

Renal Transplantation Outcomes and TreatmentsPharmacological Effects and Toxicity StudiesNeurological Complications and Syndromes

MeSH Terms

Delayed-Action PreparationsFollow-Up StudiesGraft RejectionGraft SurvivalHumansImmunosuppression TherapyImmunosuppressive AgentsMycophenolic AcidProspective StudiesKidney TransplantationTacrolimusSirolimus

Keywords

MedicineTacrolimusImmunosuppressionSirolimusMycophenolic acidRenal functionInternal medicineTransplantationSurgeryKidney transplantationNephrologyUrologyProspective cohort studyGastroenterologyKidneyTransplantKidney TransplantObservationalProlonged-release Tacrolimus

Sustainable Development Goals

SDG 0: Good health and well-being

Long‐term, prolonged‐release tacrolimus‐based immunosuppression in de novo kidney transplant recipients: 5‐year prospective follow‐up of the ADHERE study patients

FAIR Checklist

DataRank Breakdown

Authors (15)

Funding (2 grants)

Impact

Open Access

Topics